Abstract
Objective: Posttraumatic stress disorder (PTSD) is frequently associated with depression and anxiety, but the nature of the relationship is unclear. By removing mood and anxiety diagnostic criteria, the 11th edition of the International Classification of Diseases (ICD-11) aims to delineate a distinct PTSD phenotype. We examined the effect of implementing ICD-11 criteria on rates of codiagnosed depression and anxiety in survivors with recent PTSD. Method: Participants were 1,061 survivors of traumatic injury admitted to acute care centers in Israel. ICD-10 and ICD-11 diagnostic rules were applied to the Clinician-Administered PTSD Scale for DSM-IV. Co-occurring disorders were identified using the Structured Clinical Interview for DSM-IV (SCID). Depression severity was measured by the Beck Depression Inventory-II (BDI-II). Assessments were performed 0–60 (“wave 1”) and 90–240 (“wave 2”) days after trauma exposure. Results: Participants identified by ICD-11 PTSD criteria were equally or more likely than those identified by the ICD-10 alone to meet depression or anxiety disorder diagnostic criteria (for wave 1: depressive disorders, OR [odds ratio] = 1.98, 95% CI [confidence interval] = [1.36, 2.87]; anxiety disorders, OR = 1.04, 95% CI = [0.67, 1.64]; for wave 2: depressive disorders, OR = 1.70, 95% CI = [1.00, 2.91]; anxiety disorders, OR = 1.04, 95% CI = [0.54, 2.01]). ICD-11 PTSD was associated with higher BDI scores (M = 23.15 vs. 17.93, P < 0.001 for wave 1; M = 23.93 vs. 17.94, P < 0.001 for wave 2). PTSD symptom severity accounted for the higher levels of depression in ICD-11 PTSD. Conclusions: Despite excluding depression and anxiety symptom criteria, the ICD-11 identified equal or higher proportion of depression and anxiety disorders, suggesting that those are inherently associated with PTSD.
Original language | English |
---|---|
Pages (from-to) | 490-498 |
Number of pages | 9 |
Journal | Depression and Anxiety |
Volume | 36 |
Issue number | 6 |
Early online date | 25 Jan 2019 |
DOIs | |
Publication status | Published - Jun 2019 |
Funding
informatiomUS Public Health Service research grant #MH101227 to Arieh Shalev, Ronald Kessler, and Karestan Koenen.We are grateful for the contributions of Paul O'Connor at the Nathan Kline Institute for his invaluable assistance in data management and quality assurance. This study was funded by the US Public Health Service research grant (MH101227) to Arieh Shalev, Ronald Kessler, and Karestan Koenen. Dr. Matsuoka reports personal fees from Morinaga Milk, Eli Lilly, and NTT Data. Over the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. We are grateful for the contributions of Paul O'Connor at the Nathan Kline Institute for his invaluable assistance in data management and quality assurance. This study was funded by the US Public Health Service research grant (MH101227) to Arieh Shalev, Ronald Kessler, and Karestan Koenen. US Public Health Service research grant #MH101227 to Arieh Shalev, Ronald Kessler, and Karestan Koenen.
Funders | Funder number |
---|---|
Johnson & Johnson Services Inc. | |
Johnson & Johnson Wellness and Prevention | |
Sanofi Aventis | |
US Public Health Service | 101227 |
National Institute of Mental Health | R01MH101227 |
Eli Lilly and Company | |
Shire | |
Neelan Tiruchelvam Trust | |
informatiomUS Public Health Service |
Keywords
- anxiety disorders
- comorbidity
- depressive disorders
- nosology
- posttraumatic stress disorder